Cns Drugs

Journal Title：Cns Drugs

CNS Drugs promotes rational pharmacotherapy within the disciplines of clinical psychiatry and neurology. The Journal includes:

- Overviews of contentious or emerging issues.

- Comprehensive narrative reviews that provide an authoritative source of information on pharmacological approaches to managing neurological and psychiatric illnesses.

- Systematic reviews that collate empirical evidence to answer a specific research question, using explicit, systematic methods as outlined by the PRISMA statement.

- Adis Drug Reviews of the properties and place in therapy of both newer and established drugs in neurology and psychiatry.

- Original research articles reporting the results of well-designed studies with a strong link to clinical practice, such as clinical pharmacodynamic and pharmacokinetic studies, clinical trials, meta-analyses, outcomes research, and pharmacoeconomic and pharmacoepidemiological studies.

Additional digital features (including animated abstracts, video abstracts, slide decks, audio slides, instructional videos, infographics, podcasts and animations) can be published with articles; these are designed to increase the visibility, readership and educational value of the journal’s content. In addition, articles published in CNS Drugs may be accompanied by plain language summaries to assist readers who have some knowledge of, but not in-depth expertise in, the area to understand important medical advances.

CNS Drugs 致力于促进临床精神病学和神经病学学科内的合理药物治疗。该期刊包括：

- 有争议或新兴问题的概述。

- 全面的叙述性评论，提供有关治疗神经和精神疾病的药理学方法的权威信息来源。

- 系统评价，使用 PRISMA 声明概述的明确、系统方法，汇总经验证据以回答特定的研究问题。

- Adis 药物评论，介绍神经病学和精神病学中新药和成熟药物的特性和治疗地位。

- 原创研究文章，报告精心设计的研究结果，与临床实践密切相关，例如临床药效学和药代动力学研究、临床试验、荟萃分析、结果研究以及药物经济学和药物流行病学研究。

其他数字功能（包括动画摘要、视频摘要、幻灯片、音频幻灯片、教学视频、信息图表、播客和动画（英语：Animals）可以与文章一起发表；这些旨在提高期刊内容的可见性、读者群和教育价值。此外，在 CNS Drugs 上发表的文章可能会附有通俗易懂的摘要，以帮助对该领域有一定了解但不具备深入专业知识的读者了解重要的医学进展。

Cns Drugs创刊于1994年，由Springer International Publishing出版商出版，收稿方向涵盖医学 - 精神病学全领域，此刊是该细分领域中属于非常不错的SCI期刊，在行业细分领域中学术影响力较大，专业度认可很高，所以对原创文章要求创新性较高，如果您的文章质量很高，可以尝试。平均审稿速度 较慢,6-12周 ，影响因子指数7.4，该期刊近期没有被列入国际期刊预警名单，广大学者值得一试。